Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation

Research output: Contribution to journal › Review › Research › peer-review

Standard

Implementing targeted therapies in the treatment of glioblastoma : Previous shortcomings, future promises, and a multimodal strategy recommendation. / Fougner, Vincent; Hasselbalch, Benedikte; Lassen, Ulrik; Weischenfeldt, Joachim; Poulsen, Hans Skovgaard; Urup, Thomas.

In: Neuro-Oncology Advances, Vol. 4, No. 1, vdac157, 2022.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Fougner, V, Hasselbalch, B, Lassen, U, Weischenfeldt, J, Poulsen, HS & Urup, T 2022, 'Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation', Neuro-Oncology Advances, vol. 4, no. 1, vdac157. https://doi.org/10.1093/noajnl/vdac157

APA

Fougner, V., Hasselbalch, B., Lassen, U., Weischenfeldt, J., Poulsen, H. S., & Urup, T. (2022). Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation. Neuro-Oncology Advances, 4(1), [vdac157]. https://doi.org/10.1093/noajnl/vdac157

Vancouver

Fougner V, Hasselbalch B, Lassen U, Weischenfeldt J, Poulsen HS, Urup T. Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation. Neuro-Oncology Advances. 2022;4(1). vdac157. https://doi.org/10.1093/noajnl/vdac157

Author

Fougner, Vincent ; Hasselbalch, Benedikte ; Lassen, Ulrik ; Weischenfeldt, Joachim ; Poulsen, Hans Skovgaard ; Urup, Thomas. / Implementing targeted therapies in the treatment of glioblastoma : Previous shortcomings, future promises, and a multimodal strategy recommendation. In: Neuro-Oncology Advances. 2022 ; Vol. 4, No. 1.

Bibtex

@article{006fb193ac3a480bb4617b92e75e9cc4,
title = "Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation",
abstract = "The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.",
keywords = "glioblastoma, real-world evidence, targeted treatment, translational research, trial design",
author = "Vincent Fougner and Benedikte Hasselbalch and Ulrik Lassen and Joachim Weischenfeldt and Poulsen, {Hans Skovgaard} and Thomas Urup",
note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.",
year = "2022",
doi = "10.1093/noajnl/vdac157",
language = "English",
volume = "4",
journal = "Neuro-Oncology Advances",
issn = "2632-2498",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Implementing targeted therapies in the treatment of glioblastoma

T2 - Previous shortcomings, future promises, and a multimodal strategy recommendation

AU - Fougner, Vincent

AU - Hasselbalch, Benedikte

AU - Lassen, Ulrik

AU - Weischenfeldt, Joachim

AU - Poulsen, Hans Skovgaard

AU - Urup, Thomas

N1 - Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

PY - 2022

Y1 - 2022

N2 - The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.

AB - The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.

KW - glioblastoma

KW - real-world evidence

KW - targeted treatment

KW - translational research

KW - trial design

U2 - 10.1093/noajnl/vdac157

DO - 10.1093/noajnl/vdac157

M3 - Review

C2 - 36325372

AN - SCOPUS:85145418458

VL - 4

JO - Neuro-Oncology Advances

JF - Neuro-Oncology Advances

SN - 2632-2498

IS - 1

M1 - vdac157

ER -

ID: 335697875